Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06265688 · ClinicalTrials.gov registry record · Phase 1

First In Human Study of CX-2051 in Advanced Solid Tumors

A Phase 1 study of Solid Tumor, Adult, sponsored by CytomX Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
160
Enrollment target
4
Study locations

NCT06265688 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by CytomX Therapeutics. The registered enrollment target is 160 participants, below the 188-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (15% lower). The trial reports 4 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06265688, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by CytomX Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
160 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.

Conditions Studied

Solid Tumor, Adult

Interventions

  • DRUG Bevacizumab
  • DRUG CX-2051

Study Locations (4)

Colorado

  • Sarah Cannon Research Institute at HealthONE - Denver

Massachusetts

  • Dana-Farber Cancer Institute - Boston

North Carolina

  • Carolina BioOncology Institute, PLLC - Huntersville

Tennessee

  • Sarah Cannon Research Institute, LLC - Nashville

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2024-04-02
Est. Completion 2029-03-31
Phase Phase 1

Sponsor

CytomX Therapeutics

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06265688

The ClinicalTrials.gov registry entry for NCT06265688 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 188-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (15% lower). The listed sponsor is CytomX Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 2 interventions - of which Bevacizumab is the first listed.

NCT06265688 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Colorado, Massachusetts, North Carolina.

Frequently Asked Questions

What is clinical trial NCT06265688 about?

NCT06265688 is a clinical study titled "First In Human Study of CX-2051 in Advanced Solid Tumors". The purpose of this first-in-human study, CTMX-2051-101, is to characterize the safety, tolerability, and antitumor activity of CX-2051 as a monotherapy and in combination with bevacizumab in adult participants with advanced solid tumors.

What is the current status of trial NCT06265688?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2024-04-02. Estimated completion is 2029-03-31.

What conditions does trial NCT06265688 study?

This clinical trial studies the following conditions: Solid Tumor, Adult.

What interventions are being tested in trial NCT06265688?

The interventions under investigation include: Bevacizumab (DRUG), CX-2051 (DRUG).

Who is sponsoring clinical trial NCT06265688?

This trial is sponsored by CytomX Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06265688 being conducted?

This trial has 4 study locations across Colorado, Massachusetts, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumor, Adult

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumor, Adult

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.